A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Vecuronium

Nondepolarizing Neuromuscular Blocker class · 9 generic manufacturers · 18 ANDAs filed at FDA.

First FDA approval2014-03-20
Generic availableYes · 9 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema8 entries indexed · 4 visible
What is Vecuronium used for?

Vecuronium is a Nondepolarizing Neuromuscular Blocker medication tracked in Medicare Part D.

Is there a generic for Vecuronium?

Yes. 18 ANDAs filed at FDA, 9 generic manufacturers currently shipping.

How much does my plan pay for Vecuronium?

NADAC pricing data not currently available for this drug.

Is Vecuronium on the FDA shortage list?

Vecuronium has been discontinued by its manufacturer(s).

4 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Nondepolarizing Neuromuscular Blocker3 alternatives in D1
01
Atracurium
Nondepolarizing Neuromuscular Blocker
Lowest NADAC
3Generic mfrs
CY24 Part D spend
Compare →
02
Cisatracurium
Brand: Cisatracurium
Lowest NADAC
10Generic mfrs
CY24 Part D spend
Compare →
03
Rocuronium
Brand: Rocuronium
$0.394Lowest NADAC
18Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.